OXNARD, Calif., Jan. 03, 2018 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, will be a presenting company at the 2018 Biotech Showcase in San Francisco, CA, taking place January 8 -10, 2018.
“We look forward to sharing how CURE can improve the delivery of pharmaceuticals to improve patient outcomes and save money,” said Robert Davidson, CEO of CURE Pharmaceutical. “This has been a pivotal year. In addition to proving our technology’s effectiveness for pharmaceuticals, we’ve also expanded our patent portfolio, forged new partnerships with cutting-edge companies looking for new methods to deliver their proprietary molecules and attracted industry veterans to join our management team and board.
CURE will be presenting on January 10th at 9:30am. If you are interested in scheduling a meeting at the conference with CURE executives, please contact Euvy Tatunay at [email protected].
This event is considered a critical strategic benchmark for business development activities and is one of the year’s most important investor conferences. Biotech Showcase attracts a wide range of business leaders from large and midsize pharmaceutical companies, investors and other industry experts.
About CURE Pharmaceutical
CURE Pharmaceutical is a fully integrated life science company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Forward-looking statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Public Relations Contact
Andrew Hard
Chief Executive Officer
CMW Media
[email protected]
P. +1888 829-0070
www.cmwmedia.com


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Instagram Outage Disrupts Thousands of U.S. Users
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Washington Post Publisher Will Lewis Steps Down After Layoffs
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 



